About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
CEO and Founder: Jan G. J. van de Winkel, Ph.D.
CFO: David Eatwell
JOBS: Please click here for Genmab job opportunities.
Please click here for clinical trial information.
FOLLOW GENMAB: Tweets by Genmab
357 articles with Genmab A/S
Genmab A/S Release: Ofatumumab And Daratumumab Data To Be Presented At 20th Congress Of European Hematology Association
Capital Increase In Genmab A/S As A Result Of Employee Warrant Exercise And Projection Of Improved Cash Position At The End Of 2015
Genmab A/S Announces That Agreement To Transfer Ofatumumab Collaboration To Novartis AG Is Now Effective
Genmab A/S Announces Preliminary Results In Phase 2 Study Of Daratumumab In Double Refractory Multiple Myeloma
Genmab A/S Announces Additional Data From Phase 3 Study Of Ofatumumab As Maintenance Therapy For Relapsed CLL